Surgical oncology

OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care

Retrieved on: 
Monday, March 27, 2023

OncoNano Medicine, Inc. presented data from a Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for image-guided cancer surgery, at the Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care, occurring March 22-25 in Boston, MA.

Key Points: 
  • OncoNano Medicine, Inc. presented data from a Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for image-guided cancer surgery, at the Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care, occurring March 22-25 in Boston, MA.
  • Data from the study revealed that the primary endpoint was achieved in 50% of the evaluable patients undergoing peritoneal carcinomatosis surgery.
  • The primary objective of this Phase 2 study was to determine if the administration of pegsitacianine (1 mg/kg) prior to surgery results in the detection of additional disease following standard of care surgical resection of peritoneal metastases.
  • “These results show that pegsitacianine can safely be administered up to three days in advance of surgery, without any impact on the planned surgical approach.

Two Renowned Cancer Experts to Head New Tisch Cancer Hospital at The Mount Sinai Hospital

Retrieved on: 
Thursday, March 16, 2023

NEW YORK, March 16, 2023 /PRNewswire-PRWeb/ -- Two top cancer experts have been named to lead Mount Sinai's new Tisch Cancer Hospital, which is under development and due to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief of the Tisch Cancer Hospital.

Key Points: 
  • Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief of the Tisch Cancer Hospital.
  • The Tisch Cancer Hospital will be a state-of-the-art cancer facility at The Mount Sinai Hospital, thanks to a generous $60 million gift from James S. and Merryl H. Tisch.
  • "Mount Sinai's vision for the Tisch Cancer Hospital was bold," said Mr. Tisch, Co-Chairman of the Boards of Trustees of the Mount Sinai Health System.
  • "The Tisch Cancer Hospital will be a hospital within the hospital that is supported by experts from various areas of medicine," Dr. Tewari said.

Namida Lab Drives Expansion by Appointing Advisory Board and Announcing Organizational Changes

Retrieved on: 
Tuesday, February 28, 2023

Namida Lab , the world leader in tear-based cancer screening, announces the appointment of an advisory board composed of leaders from breast oncology and radiology, healthcare strategy, and consumer marketing fields.

Key Points: 
  • Namida Lab , the world leader in tear-based cancer screening, announces the appointment of an advisory board composed of leaders from breast oncology and radiology, healthcare strategy, and consumer marketing fields.
  • Clinical Advisory Board Member Dr. V. Suzanne Klimberg, MD, PhD, has over 30 years of experience in breast surgical oncology.
  • Additionally, Dr. Klimberg has won over 75 awards in teaching, research, and clinical care and is a Senior Director for the American Board of Surgery, the American Board of Plastic Surgery, and the American Board of Complex Surgical Oncology.
  • Advisory Board Member Marcus Osborne is the CEO of RightMove, a nationwide virtual musculoskeletal physical therapy provider.

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

Retrieved on: 
Thursday, February 23, 2023

I am encouraged by the positive interim results of the light-activated, intravesical study drug TLD-1433 (Trade Name: Ruvidar) currently under investigation by Theralase® in Study II.

Key Points: 
  • I am encouraged by the positive interim results of the light-activated, intravesical study drug TLD-1433 (Trade Name: Ruvidar) currently under investigation by Theralase® in Study II.
  • The interim analysis of the clinical data collected from Study II to date supports that early results show complete response rates in 53% of patients evaluated at 90 days and 28% of patients evaluated at 450 days.
  • Based on the clinical data presented to date, Rudivar could represent a viable treatment option with an acceptable safety profile.
  • One day we hope that Ruvidar™ will become the organ-sparing solution that is a game-changer for both patients and physicians.”

MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers

Retrieved on: 
Wednesday, February 1, 2023

HOUSTON and SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Federation Bio, a biotechnology company pioneering bacterial cell therapies, today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy. The agreement pairs Federation Bio's proprietary ACT™ (anerobic co-culture technology) platform with the expertise and capabilities of MD Anderson's Platform for Innovative Microbiome and Translational Research (PRIME-TR). 

Key Points: 
  • The agreement pairs Federation Bio's proprietary ACT™ (anerobic co-culture technology) platform with the expertise and capabilities of MD Anderson's Platform for Innovative Microbiome and Translational Research (PRIME-TR).
  • Under the agreement, MD Anderson and Federation Bio intend to rationally design a complex consortium of bacteria derived from a donor fecal sample that has a demonstrated ability to improve immunotherapy responses in cancer patients via FMT in a clinical trial.
  • Federation Bio currently is evaluating FB-001 in a Phase I clinical trial; it is the first rationally designed complex consortium at this scale to enter clinical studies.
  • PRIME-TR is a novel institutional platform that aims to transform the landscape of cancer treatment, diagnosis and prevention through studying and targeting the microbiome at multiple different niches.

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

Retrieved on: 
Thursday, February 2, 2023

The AUA annual meeting will take place between April 28th to May 1st, 2023 in Chicago, Illinois with the poster presented for general viewing and discussion within one of the moderated poster sessions, during the AUA annual meeting.

Key Points: 
  • The AUA annual meeting will take place between April 28th to May 1st, 2023 in Chicago, Illinois with the poster presented for general viewing and discussion within one of the moderated poster sessions, during the AUA annual meeting.
  • The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.
  • Arkady Mandel MD, Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, “I am delighted that Theralase® will have the opportunity to showcase its latest reported interim clinical data and analysis for Study II at the AUA annual meeting to leading uro-oncologists from around the world.
  • Based on the clinical data collected to date, PDT could represent a viable treatment option with an acceptable safety profile.”

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

Retrieved on: 
Wednesday, January 25, 2023

The GU-ASCO cancer symposium will take place between February 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM.

Key Points: 
  • The GU-ASCO cancer symposium will take place between February 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM.
  • The poster titled: “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (interim analysis)” will be presented by the lead author, Girish Kulkarni M.D., Ph.D., FRCSC, Divisions of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Professor, University of Toronto, (Toronto, Ontario, Canada).
  • The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.
  • Arkady Mandel MD, Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, “I am delighted that Theralase® will have the opportunity to showcase its latest reported interim clinical data and analysis for Study II at the coveted ASCO GU Cancer Symposium to leading uro-oncologists from around the world.”

Indian Researchers from ACTREC Discover Novel Therapeutic Agent for a Host of Diseases

Retrieved on: 
Tuesday, January 17, 2023

MUMBAI, India, Jan. 17, 2023 /PRNewswire/ -- Chromatin comprises a complex mixture of DNA and proteins and forms the structural basis of chromosomes in the cellular nuclei. When cells die, they release cell-free chromatin particles or "cfChPs" into the circulatory system. Emerging evidence indicates that cfChPs exert toxic effects by damaging the DNA of healthy cells and activating pro-inflammatory processes. Researchers from the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), India, have recently demonstrated therapeutic benefits of a pro-oxidant mixture of resveratrol and copper, R-Cu, in patients undergoing chemotherapy for advanced gastric cancer. Combining R with Cu (R-Cu) leads to the generation of free oxygen radicals which can inactivate the offending cfChPs.

Key Points: 
  • When cells die, they release cell-free chromatin particles or "cfChPs" into the circulatory system.
  • Emerging evidence indicates that cfChPs exert toxic effects by damaging the DNA of healthy cells and activating pro-inflammatory processes.
  • Researchers from the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), India, have recently demonstrated therapeutic benefits of a pro-oxidant mixture of resveratrol and copper, R-Cu, in patients undergoing chemotherapy for advanced gastric cancer .
  • Combining R with Cu (R-Cu) leads to the generation of free oxygen radicals which can inactivate the offending cfChPs.

University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems

Retrieved on: 
Thursday, January 5, 2023

DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase of up to four systems, and will be the first in Ohio at a research and teaching hospital to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, kidney, gynecological, lung, liver, breast, brain, spine, and oligometastatic cancers.

Key Points: 
  • UH Seidman Cancer Center is part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine.
  • "UH Seidman Cancer Center is at the forefront of clinical excellence and transformative innovation.
  • There was unanimous multi-disciplinary support to bring ViewRay's MRIdian MRI-guided radiotherapy to our center and provide our patients with the latest radiotherapeutic advancements.
  • We aim to continue the advancement of MR-guided adaptive radiotherapy through cutting-edge clinical trials and research to improve patient outcomes.

Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

Retrieved on: 
Tuesday, December 13, 2022

The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”).

Key Points: 
  • The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”).
  • “Beyond Cancer’s novel implementation of ultra-high concentrations of nitric oxide to treat solid tumors has repeatedly resulted in data demonstrating an immunostimulatory response,” stated Dr. Hila Confino, Chief Scientific Officer.
  • Two weeks post gas treatment, the tumors were resected and a week later a secondary tumor was induced in the contralateral flank.
  • In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models.